Sp62
INNOVATIONS IN MANAGEMENT OF BARRETT'S ESOPHAGUS
Date
May 18, 2024
Presenter
Mayo Clinic
Tracks
Related Products
AI Beyond the Endoscope: How AI is Revolutionizing GI Practice
This session looks at the rapidly growing applications and impacts of AI beyond endoscopy in the GI world, including office tools, scribes, billing resources, EHR tools etc…
CLINICAL OUTCOMES AFTER ENDOSCOPIC MANAGEMENT OF LOW-RISK AND HIGH-RISK T1A ESOPHAGEAL ADENOCARCINOMA : OUTCOMES FROM A LARGE COHORT
Focal cryoballoon ablation (FCBA) is a relatively new ablation modality for the treatment of Barrett’s esophagus (BE) related neoplasia. This prospective, European multicenter study (Euro-Coldplay, NTR NL7253) aimed to evaluate the efficacy and safety of FCBA for the treatment of limited BE…
VALIDATION OF COPY NUMBER ABERRATION AND METHYLATED DNA MARKERS FOR DIFFERENTIATION OF NON-DYSPLASTIC BARRETT’S ESOPHAGUS FROM BARRETT’S ESOPHAGUS WITH HIGH GRADE DYSPLASIA AND ESOPHAGEAL ADENOCARCINOMA : A MULTICENTER STUDY
Endoscopic surveillance of Barrett’s esophagus (BE) is recommended to identify dysplasia (low grade [LGD], high grade [HGD]) or adenocarcinoma [EAC]) for endoscopic intervention. However, this paradigm is limited by sampling error and subtle endoscopic changes, leading to missed HGD and EAC…
JOURNEY TO COMPLETE REMISSION OF DYSPLASIA AND INTESTINAL METAPLASIA AFTER ENDOSCOPIC ERADICATION THERAPY OF BARRETT’S ESOPHAGUS RELATED DYSPLASIA AND ADENOCARCINOMA: A COMPARATIVE ANALYSIS OF ESD VS EMR RESULTS FROM A MULTICENTER NORTH AMERICAN COHORT
Focal cryoballoon ablation (FCBA) is a relatively new ablation modality for the treatment of Barrett’s esophagus (BE) related neoplasia. This prospective, European multicenter study (Euro-Coldplay, NTR NL7253) aimed to evaluate the efficacy and safety of FCBA for the treatment of limited BE…